Biopharmaceutical Bioseparation Systems

Biopharmaceutical Bioseparation Systems

Global Biopharmaceutical Bioseparation Systems Market to Reach US$32.6 Billion by 2030

The global market for Biopharmaceutical Bioseparation Systems estimated at US$15.7 Billion in the year 2023, is expected to reach US$32.6 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2023-2030. Chromatography Technology, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$15.8 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 11.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.5 Billion While China is Forecast to Grow at 13.5% CAGR

The Biopharmaceutical Bioseparation Systems market in the U.S. is estimated at US$6.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 13.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.0% CAGR.

Global Biopharmaceutical Bioseparation Systems Market - Key Trends & Drivers Summarized

Biopharmaceutical bioseparation systems are critical components in the production and purification of biopharmaceuticals, which include therapeutic proteins, monoclonal antibodies, and vaccines. These systems employ various techniques such as chromatography, filtration, and centrifugation to separate and purify biological molecules from complex mixtures. The demand for biopharmaceuticals is increasing due to their effectiveness in treating chronic and rare diseases, driving the need for efficient and reliable bioseparation systems. These systems are essential for ensuring the purity, potency, and safety of biopharmaceutical products, which are subject to stringent regulatory requirements. Advances in bioseparation technologies are enhancing the efficiency and scalability of biopharmaceutical manufacturing processes.

The biopharmaceutical bioseparation market is experiencing significant growth due to the expanding biopharmaceutical industry and the increasing adoption of advanced bioseparation techniques. The rise in the prevalence of chronic diseases, the aging population, and the growing demand for personalized medicine are fueling the production of biopharmaceuticals. Additionally, the development of novel therapies such as gene and cell therapies is creating new challenges and opportunities for bioseparation technologies. Innovations in materials and methods, such as the use of single-use systems and continuous processing, are improving the efficiency and cost-effectiveness of bioseparation processes. These advancements are enabling the production of high-quality biopharmaceuticals at larger scales.

The growth in the biopharmaceutical bioseparation systems market is driven by several factors. Firstly, the increasing demand for biopharmaceuticals, driven by the prevalence of chronic diseases and the aging population, is boosting the need for efficient bioseparation systems. Secondly, advancements in bioseparation technologies, including single-use systems and continuous processing, are enhancing the scalability and cost-effectiveness of biopharmaceutical manufacturing. Thirdly, the development of novel therapies such as gene and cell therapies is creating new challenges and opportunities for bioseparation, driving innovation in this field. Lastly, stringent regulatory requirements for biopharmaceutical products are necessitating the use of advanced bioseparation systems to ensure product quality and safety. These factors collectively contribute to the robust growth of the biopharmaceutical bioseparation systems market.

Select Competitors (Total 61 Featured) -

• 3M Company
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Alfa Laval AB
• GEA Group AG
• AMS Biotechnology (Europe) Ltd. (amsbio)
• Biotage AB
• AnteoTech
• BIA Separations d.o.o.
• Heinkel Drying and Separation Group
• 3B Pharmaceuticals GmbH
• Critical Process Filtration, Inc.
• Flottweg SE
• Ellutia
• Global Life Sciences Solutions USA LLC (Cytiva)

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.